RU2012137180A - Гетероциклические ингибиторы гистаминовых рецепторов для лечения заболеваний - Google Patents
Гетероциклические ингибиторы гистаминовых рецепторов для лечения заболеваний Download PDFInfo
- Publication number
- RU2012137180A RU2012137180A RU2012137180/04A RU2012137180A RU2012137180A RU 2012137180 A RU2012137180 A RU 2012137180A RU 2012137180/04 A RU2012137180/04 A RU 2012137180/04A RU 2012137180 A RU2012137180 A RU 2012137180A RU 2012137180 A RU2012137180 A RU 2012137180A
- Authority
- RU
- Russia
- Prior art keywords
- optionally substituted
- heterocycloalkyl
- compound according
- heteroaryl
- cycloalkyl
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 8
- 201000010099 disease Diseases 0.000 title claims 6
- 102000000543 Histamine Receptors Human genes 0.000 title 1
- 108010002059 Histamine Receptors Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 43
- 125000000217 alkyl group Chemical group 0.000 claims abstract 41
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 33
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 33
- 125000003118 aryl group Chemical group 0.000 claims abstract 31
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 30
- 239000001257 hydrogen Substances 0.000 claims abstract 30
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 28
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 27
- 125000004103 aminoalkyl group Chemical group 0.000 claims abstract 26
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract 21
- 150000002431 hydrogen Chemical class 0.000 claims abstract 20
- 150000003839 salts Chemical class 0.000 claims abstract 19
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 15
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract 15
- 229910052736 halogen Inorganic materials 0.000 claims abstract 15
- 150000002367 halogens Chemical class 0.000 claims abstract 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 15
- -1 C-amido Chemical group 0.000 claims abstract 14
- 125000002252 acyl group Chemical group 0.000 claims abstract 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 14
- 125000004404 heteroalkyl group Chemical group 0.000 claims abstract 14
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims abstract 14
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 12
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims abstract 9
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 8
- 125000003368 amide group Chemical group 0.000 claims abstract 8
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 8
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract 6
- 229910052799 carbon Inorganic materials 0.000 claims abstract 5
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 125000002950 monocyclic group Chemical group 0.000 claims 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 6
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 5
- 208000010668 atopic eczema Diseases 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 229930192474 thiophene Natural products 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 230000000172 allergic effect Effects 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 claims 3
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 claims 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 210000001508 eye Anatomy 0.000 claims 3
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims 3
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 3
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 claims 3
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 claims 3
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 3
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 206010028735 Nasal congestion Diseases 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 2
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 claims 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 206010015943 Eye inflammation Diseases 0.000 claims 1
- 206010015958 Eye pain Diseases 0.000 claims 1
- 206010018258 Giant papillary conjunctivitis Diseases 0.000 claims 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims 1
- 206010028741 Nasal inflammation Diseases 0.000 claims 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 claims 1
- 208000005141 Otitis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010040742 Sinus congestion Diseases 0.000 claims 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical group C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 229960004574 azelastine Drugs 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 229940092705 beclomethasone Drugs 0.000 claims 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
- 229960003166 bromazine Drugs 0.000 claims 1
- ZQDJSWUEGOYDGT-UHFFFAOYSA-N bromazine hydrochloride Chemical compound [Cl-].C=1C=C(Br)C=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 ZQDJSWUEGOYDGT-UHFFFAOYSA-N 0.000 claims 1
- 229960000725 brompheniramine Drugs 0.000 claims 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 229960001803 cetirizine Drugs 0.000 claims 1
- 229960003291 chlorphenamine Drugs 0.000 claims 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims 1
- 229960002881 clemastine Drugs 0.000 claims 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 229960000520 diphenhydramine Drugs 0.000 claims 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000005069 ears Anatomy 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 229960000930 hydroxyzine Drugs 0.000 claims 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims 1
- 210000004969 inflammatory cell Anatomy 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 229960004958 ketotifen Drugs 0.000 claims 1
- 229960001120 levocabastine Drugs 0.000 claims 1
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 claims 1
- 229960001508 levocetirizine Drugs 0.000 claims 1
- 229960003088 loratadine Drugs 0.000 claims 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960004056 methdilazine Drugs 0.000 claims 1
- HTMIBDQKFHUPSX-UHFFFAOYSA-N methdilazine Chemical compound C1N(C)CCC1CN1C2=CC=CC=C2SC2=CC=CC=C21 HTMIBDQKFHUPSX-UHFFFAOYSA-N 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 229960001664 mometasone Drugs 0.000 claims 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims 1
- 210000002850 nasal mucosa Anatomy 0.000 claims 1
- 208000037916 non-allergic rhinitis Diseases 0.000 claims 1
- 229960004114 olopatadine Drugs 0.000 claims 1
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 claims 1
- CMGNFILMNHGISN-UHFFFAOYSA-N oxadiazole;thiadiazole Chemical compound C1=CON=N1.C1=CSN=N1 CMGNFILMNHGISN-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960003910 promethazine Drugs 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 238000006748 scratching Methods 0.000 claims 1
- 230000002393 scratching effect Effects 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 229960001128 triprolidine Drugs 0.000 claims 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 claims 1
- 0 *c([n]1c2nnc1)cnc2N1CCCCCC1 Chemical compound *c([n]1c2nnc1)cnc2N1CCCCCC1 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31261510P | 2010-03-10 | 2010-03-10 | |
| US61/312,615 | 2010-03-10 | ||
| PCT/US2011/027817 WO2011112766A2 (en) | 2010-03-10 | 2011-03-10 | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012137180A true RU2012137180A (ru) | 2014-04-20 |
Family
ID=44564108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012137180/04A RU2012137180A (ru) | 2010-03-10 | 2011-03-10 | Гетероциклические ингибиторы гистаминовых рецепторов для лечения заболеваний |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8569300B2 (enExample) |
| EP (1) | EP2545058B1 (enExample) |
| JP (1) | JP5888654B2 (enExample) |
| KR (1) | KR20130016253A (enExample) |
| CN (1) | CN102869666B (enExample) |
| AR (1) | AR080496A1 (enExample) |
| AU (1) | AU2011224316B2 (enExample) |
| BR (1) | BR112012022211A2 (enExample) |
| CA (1) | CA2791417A1 (enExample) |
| ES (1) | ES2607125T3 (enExample) |
| IL (1) | IL221829A (enExample) |
| MX (1) | MX2012010404A (enExample) |
| NZ (1) | NZ602041A (enExample) |
| PH (1) | PH12012501783A1 (enExample) |
| RU (1) | RU2012137180A (enExample) |
| TW (1) | TW201200518A (enExample) |
| UY (1) | UY33271A (enExample) |
| WO (1) | WO2011112766A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013039785A2 (en) * | 2011-09-12 | 2013-03-21 | Kalypsys, Inc. | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| US9266891B2 (en) | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
| CN105164134B (zh) | 2013-05-02 | 2017-09-22 | 辉瑞大药厂 | 作为pde10抑制剂的咪唑并‑三嗪衍生物 |
| LT3057586T (lt) | 2013-10-18 | 2020-03-10 | Celgene Quanticel Research, Inc. | Bromodomeno inhibitoriai |
| ES2750956T3 (es) | 2014-02-13 | 2020-03-30 | Incyte Corp | Ciclopropilaminas como inhibidores de LSD1 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| JP6602778B2 (ja) | 2014-02-13 | 2019-11-06 | インサイト・コーポレイション | Ｌｓｄ１阻害剤としてのシクロプロピルアミン類 |
| TW201613860A (en) | 2014-02-13 | 2016-04-16 | Incyte Corp | Cyclopropylamines as LSD1 inhibitors |
| US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
| WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
| UY36462A (es) | 2014-12-23 | 2016-07-29 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos |
| EA201792205A1 (ru) | 2015-04-03 | 2018-02-28 | Инсайт Корпорейшн | Гетероциклические соединения как ингибиторы lsd1 |
| BR112018002553A8 (pt) | 2015-08-12 | 2023-01-24 | Incyte Corp | Sais de um inibidor de lsd1 |
| PE20190377A1 (es) | 2016-04-22 | 2019-03-08 | Incyte Corp | Formulaciones de un inhibidor de lsd 1 |
| CN109790166A (zh) | 2016-06-20 | 2019-05-21 | 诺华股份有限公司 | 咪唑并吡啶化合物用于治疗癌症 |
| EP3472161B1 (en) | 2016-06-20 | 2020-03-25 | Novartis AG | Triazolopyridine compounds and uses thereof |
| KR102519922B1 (ko) | 2016-06-20 | 2023-04-11 | 노파르티스 아게 | 트리아졸로피리미딘 화합물의 결정질 형태 |
| TW201837036A (zh) | 2017-01-10 | 2018-10-16 | 德商拜耳廠股份有限公司 | 作為除害劑之雜環衍生物（一） |
| WO2018130443A1 (de) | 2017-01-10 | 2018-07-19 | Bayer Aktiengesellschaft | Heterocyclen-derivate als schädlingsbekämpfungsmittel |
| IL296456A (en) | 2017-01-23 | 2022-11-01 | Revolution Medicines Inc | Bicyclics as allosteric shp2 inhibitors |
| KR20200036004A (ko) | 2017-08-01 | 2020-04-06 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 키나아제 억제제로서 피라졸로 및 트리아졸로 비시클릭 화합물 |
| SG11202002941WA (en) * | 2017-10-12 | 2020-04-29 | Revolution Medicines Inc | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| RU2020123241A (ru) * | 2017-12-15 | 2022-01-17 | Революшн Медсинз, Инк. | Полициклические соединения в качестве аллостерических ингибиторов shp2 |
| KR102614939B1 (ko) * | 2018-02-13 | 2023-12-19 | 블루레이 테라퓨틱스 (상하이) 컴퍼니 리미티드 | 피리미딘-융합고리 화합물 및 그의 제조방법과 용도 |
| CN110655520A (zh) * | 2018-06-29 | 2020-01-07 | 上海青煜医药科技有限公司 | 嘧啶并环化合物及其制备方法和应用 |
| CN115448923B (zh) * | 2018-02-13 | 2024-03-22 | 上海青煜医药科技有限公司 | 嘧啶并环化合物及其制备方法和应用 |
| KR20200139153A (ko) | 2018-02-27 | 2020-12-11 | 인사이트 코포레이션 | A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘 |
| CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| CA3105721A1 (en) | 2018-07-05 | 2020-01-09 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
| EP3878853A4 (en) * | 2018-11-07 | 2022-12-14 | Shanghai Ringene BioPharma Co., Ltd. | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, METHOD OF PREPARATION AND USE |
| AU2019386036A1 (en) * | 2018-11-30 | 2021-05-27 | Tuojie Biotech (Shanghai) Co., Ltd. | Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof |
| CN113498352A (zh) | 2019-01-23 | 2021-10-12 | 施万生物制药研发Ip有限责任公司 | 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| EP4019521A4 (en) * | 2019-08-22 | 2023-05-03 | Blueray Therapeutics (Shanghai) Co., Ltd | AZAHETEROARYL COMPOUND AND USE |
| US12065444B2 (en) | 2021-11-19 | 2024-08-20 | Crossignal Therapeutics, Inc. | Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3929812A (en) * | 1974-05-20 | 1975-12-30 | Squibb & Sons Inc | Derivatives of 1H-triazolo {8 4,5-c{9 pyridine-7-carboxylic acids and esters |
| DE4337611A1 (de) * | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| JPWO2003028732A1 (ja) * | 2001-09-28 | 2005-01-13 | 協和醗酵工業株式会社 | 受容体拮抗剤 |
| US6921762B2 (en) * | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
| JPWO2004000841A1 (ja) * | 2002-06-25 | 2005-10-20 | 協和醗酵工業株式会社 | 二環性複素環化合物 |
| EP1545532A2 (en) | 2002-09-06 | 2005-06-29 | Janssen Pharmaceutica N.V. | Heterocyclic compounds |
| ES2317244T3 (es) * | 2004-06-09 | 2009-04-16 | Glaxo Group Limited | Derivados de pirrolopiridina. |
| EP1970373A1 (en) * | 2005-12-02 | 2008-09-17 | Mitsubishi Tanabe Pharma Corporation | Alicyclic heterocyclic compound |
| US7807671B2 (en) * | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
| DE602007006010D1 (de) * | 2006-05-31 | 2010-06-02 | Galapagos Nv | Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten |
| EP2044027A2 (en) * | 2006-07-03 | 2009-04-08 | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg | Fused bicyclic compounds interacting with the histamine h4 receptor |
| WO2008031556A2 (en) | 2006-09-12 | 2008-03-20 | Ucb Pharma, S.A. | 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions |
| EP2252619B1 (en) * | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| KR101589960B1 (ko) * | 2008-02-08 | 2016-01-29 | 바실리어 파마슈티카 아게 | Ｐｄｅ 억제를 통해 중재되는 질환의 치료를 위한 마크로라이드 |
| UY32110A (es) * | 2008-09-10 | 2010-04-30 | Alcon Res Ltd | Inhibidores de aminopirimidina de los receptores de histamina para el tratamiento de una enfermedad |
| CA2735369A1 (en) * | 2008-09-10 | 2010-03-18 | Kalypsys Inc. | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| ES2475091T3 (es) * | 2009-04-16 | 2014-07-10 | Centro Nacional De Investigaciones Oncol�Gicas (Cnio) | Imidazopirazinas como inhibidores de proteína cinasas |
| EP2789614B1 (en) * | 2009-08-11 | 2017-04-26 | Bristol-Myers Squibb Company | Azaindazoles as Btk kinase modulators and use thereof |
| WO2011075591A1 (en) | 2009-12-17 | 2011-06-23 | Merial Limited | Anti parasitic dihydroazole compounds and compositions comprising same |
| US9073927B2 (en) | 2010-01-22 | 2015-07-07 | Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii | Inhibitors of PI3 kinase |
| US20110190269A1 (en) * | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| WO2011112687A2 (en) | 2010-03-10 | 2011-09-15 | Kalypsys, Inc. | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
-
2011
- 2011-03-07 TW TW100107575A patent/TW201200518A/zh unknown
- 2011-03-10 AU AU2011224316A patent/AU2011224316B2/en not_active Ceased
- 2011-03-10 ES ES11754043.5T patent/ES2607125T3/es active Active
- 2011-03-10 NZ NZ602041A patent/NZ602041A/en not_active IP Right Cessation
- 2011-03-10 EP EP11754043.5A patent/EP2545058B1/en not_active Not-in-force
- 2011-03-10 CA CA2791417A patent/CA2791417A1/en not_active Abandoned
- 2011-03-10 KR KR1020127026253A patent/KR20130016253A/ko not_active Withdrawn
- 2011-03-10 WO PCT/US2011/027817 patent/WO2011112766A2/en not_active Ceased
- 2011-03-10 CN CN201180019492.3A patent/CN102869666B/zh not_active Expired - Fee Related
- 2011-03-10 PH PH1/2012/501783A patent/PH12012501783A1/en unknown
- 2011-03-10 BR BR112012022211A patent/BR112012022211A2/pt active Search and Examination
- 2011-03-10 MX MX2012010404A patent/MX2012010404A/es active IP Right Grant
- 2011-03-10 UY UY0001033271A patent/UY33271A/es not_active Application Discontinuation
- 2011-03-10 RU RU2012137180/04A patent/RU2012137180A/ru not_active Application Discontinuation
- 2011-03-10 US US13/044,661 patent/US8569300B2/en not_active Expired - Fee Related
- 2011-03-10 JP JP2012557231A patent/JP5888654B2/ja not_active Expired - Fee Related
- 2011-03-11 AR ARP110100765A patent/AR080496A1/es not_active Application Discontinuation
-
2012
- 2012-09-06 IL IL221829A patent/IL221829A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN102869666B (zh) | 2015-09-09 |
| JP2013522222A (ja) | 2013-06-13 |
| US8569300B2 (en) | 2013-10-29 |
| BR112012022211A2 (pt) | 2017-07-18 |
| KR20130016253A (ko) | 2013-02-14 |
| MX2012010404A (es) | 2013-05-20 |
| PH12012501783A1 (en) | 2015-06-26 |
| AU2011224316B2 (en) | 2016-09-15 |
| TW201200518A (en) | 2012-01-01 |
| EP2545058A2 (en) | 2013-01-16 |
| WO2011112766A2 (en) | 2011-09-15 |
| AU2011224316A1 (en) | 2012-09-13 |
| EP2545058A4 (en) | 2013-07-24 |
| ES2607125T3 (es) | 2017-03-29 |
| CA2791417A1 (en) | 2011-09-15 |
| NZ602041A (en) | 2014-08-29 |
| JP5888654B2 (ja) | 2016-03-22 |
| EP2545058B1 (en) | 2016-08-24 |
| US20110237565A1 (en) | 2011-09-29 |
| CN102869666A (zh) | 2013-01-09 |
| UY33271A (es) | 2011-10-31 |
| IL221829A (en) | 2014-11-30 |
| WO2011112766A3 (en) | 2012-01-19 |
| AR080496A1 (es) | 2012-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012137180A (ru) | Гетероциклические ингибиторы гистаминовых рецепторов для лечения заболеваний | |
| US9079893B2 (en) | Ureido-pyrazole derivatives for use in the treatment of respiratory syncitial virus (RSV) infection | |
| US20210363148A1 (en) | Compound having bruton's tyrosine kinase (btk)-inhibition and degradation activity | |
| US12383528B2 (en) | Cromolyn esters and uses thereof | |
| JP2013522222A5 (enExample) | ||
| US20140187554A1 (en) | Modulators of the nuclear hormone receptor ror | |
| ES2762193T3 (es) | Agonistas de proteína tirosina fosfatasa 1 que contiene dominio de homología Src-2 y métodos de tratamiento usando la misma | |
| JPH11335375A (ja) | ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体 | |
| BR112015024678B1 (pt) | Composto inibidor da cinase, formulação farmacêutica que compreende o mesmo, seus usos, processo para sua preparação e intermediários | |
| EA025158B1 (ru) | Гетероциклические соединения, лекарственные средства, содержащие указанные соединения, их применение и способы их получения | |
| AU2014236719A1 (en) | Compounds and methods for inducing chondrogenesis | |
| JP7614646B2 (ja) | 呼吸器疾患の処置のための化合物及び組成物 | |
| US11661411B2 (en) | Quinoxaline compounds and uses thereof | |
| JP5726301B2 (ja) | 新規抗ヒスタミン剤 | |
| JP4104984B2 (ja) | 抗炎症性および免疫抑制性活性を有する新規ベンズアミジン誘導体 | |
| JP2009535302A (ja) | 変形性関節炎および変形性関節症を処置するのに有用なピペリジン誘導体 | |
| JP2018503691A (ja) | 尿酸性または痛風性疾患の予防または治療 | |
| US20050065161A1 (en) | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses | |
| AU2006201177B2 (en) | Heterocyclic compounds | |
| WO2004028526A1 (ja) | ベンズアミド誘導体を有効成分とするリウマチ治療剤 | |
| ES2635240T3 (es) | N-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oxopiridin-1(2H)-il]-3,5-difluorofenil}etil]-L-alaninato de terc-butilo o una sal, hidrato o solvato del mismo | |
| WO2011058943A1 (ja) | Ｍｃｈ ｒ１アンタゴニスト活性を有する化合物とｎｐｙ ｙ５受容体アンタゴニスト活性を有する化合物を組み合わせてなる医薬組成物 | |
| US20250230151A1 (en) | Compounds for cancers driven by braf mutation | |
| US20140256711A1 (en) | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | |
| AU2001253807B2 (en) | Compositions containing a benzamide disulfide derivative for treating allergic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20151007 |